الفهرس 
Formulation and evaluation of vesicular and provesicular nanoparticles for ocular drug delivery
CONTENTSOnly 14 pages are availabe for public view
 |  | from | 228 |  |  |
| | | from | 228 | | |
Abstract
Sustained release ophthalmic gel is one of the most interesting, challenging and favorable over other ophthalmic conventional dosage forms in pharmaceutical research. Sustained release ocular drug delivery system has many advantages; decrease administered dose, low side effects, ease of application and accurate dose as well as prolonged residence time of drug in contact with mucosal membrane which leads to an increase in ocular bioavailability resulting in better inpatient compliance. Many ocular diseases may elevate the ocular pressure causing Glaucoma that occurred as a result of accumulation and backing of eye fluid leading finally to damage of the optic nerve. Glaucoma is characterized by elevated intraocular pressure IOP, cloudy cornea, haloes around lights, pain, visual field loss, occluded veins and enlargement of the eye. The ultimate prevalent types of Glaucoma are primary openangle glaucoma (POAG) and angle-closure Glaucoma. POAG is a lifelong condition that has no related manifestation while the eye pressure gradually increases by the slow plugging of the drainage canals. Other form of Glaucoma is characterized by blockage of aqueous humor draining canals resulting in a sudden elevation in the IOP and narrow angle between the iris and cornea resulting in closed-angle Glaucoma.Treatment of Glaucoma can be achieved by lowering IOP either via medical therapy or eye surgery. Most antiglaucomal drugs are classified pharmacologically into adrenergic agonists as Brimonidine, adrenergic antagonists as Timolol, cholinergic agents as Pilocarpine, derived prostaglandins as Latanoprost and carbonic anhydrase inhibitors as Dorzolamide hydrochloride